Boston Partners boosted its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 28.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 649,335 shares of the company’s stock after acquiring an additional 141,846 shares during the quarter. Boston Partners’ holdings in Novo Nordisk A/S were worth $24,612,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of Novo Nordisk A/S in the first quarter worth about $287,660,000. State Street Corp lifted its position in Novo Nordisk A/S by 0.6% during the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after acquiring an additional 32,641 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after purchasing an additional 71,684 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock valued at $166,396,000 after purchasing an additional 141,376 shares during the period. Finally, Renaissance Technologies LLC grew its position in Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after purchasing an additional 213,443 shares during the period. 11.54% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on NVO shares. DZ Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. BMO Capital Markets set a $40.00 target price on Novo Nordisk A/S and gave the company a “market perform” rating in a research report on Monday, October 12th. UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Cfra cut Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price target on the stock. in a report on Tuesday, September 22nd. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $59.44.
Novo Nordisk A/S Price Performance
NVO stock opened at $37.83 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.84 and a debt-to-equity ratio of 0.54. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The stock’s 50 day moving average is $39.59 and its two-hundred day moving average is $42.89. The company has a market capitalization of $168.90 billion, a PE ratio of 9.53, a P/E/G ratio of 1.30 and a beta of 0.70.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
